Translational Research Institute, People's Hospital of Zhengzhou University, Academy of Medical Science, Henan International Joint Laboratory of Non-coding RNA and Metabolism in Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, 450003, China.
Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230027, China.
Cell Death Dis. 2024 Jul 29;15(7):539. doi: 10.1038/s41419-024-06918-w.
Proto-oncogenic MYC is frequently dysregulated in colorectal cancer (CRC). In the past decades, long noncoding RNAs (lncRNAs) have emerged as important regulators in cancers, acting as scaffolds, molecular decoys, post-transcriptional regulators, and others. Interestingly, lncRNAs are able to control MYC expression both at transcriptional and post-transcriptional levels. It is suggested that the reciprocal interaction of MYC and lncRNAs often occurs in CRC. MYC can affect the cell fate by promoting or inhibiting the transcription of some lncRNAs. At the same time, some lncRNAs can also affect MYC expression or transcriptional activity, and in turn decide the cell fate. In this review we summarized the current knowledge about the MYC and lncRNA axis, focusing on its mutual regulation, roles in CRC, and proposed potential therapeutic prospects for CRC treatment.
原癌基因 MYC 在结直肠癌(CRC)中经常失调。在过去的几十年中,长链非编码 RNA(lncRNA)已成为癌症中重要的调控因子,发挥着支架、分子诱饵、转录后调控因子等多种作用。有趣的是,lncRNA 能够在转录和转录后水平上控制 MYC 的表达。据推测,MYC 和 lncRNA 之间的相互作用在 CRC 中经常发生。MYC 通过促进或抑制某些 lncRNA 的转录来影响细胞命运。同时,一些 lncRNA 也可以影响 MYC 的表达或转录活性,并反过来决定细胞命运。在这篇综述中,我们总结了目前关于 MYC 和 lncRNA 轴的知识,重点介绍了它们的相互调节、在 CRC 中的作用以及 CRC 治疗的潜在治疗前景。